Appeals Court Deals Blow To Pfizer

Law360, New York (March 22, 2007, 12:00 AM EDT) -- In a stinging setback for Pfizer Inc., a federal appeals court on Thursday invalidated three claims of a patent covering the company’s second-biggest drug and reversed a lower court’s decision that would have barred Canada’s Apotex Inc. from making a generic version of blockbuster hypertension drug Norvasc.

The court overturned a decision by the U.S. District Court for the Northern District of Illinois that found Apotex infringed Pfizer’s patents. It said three claims of the patent failed to meet one of the basic requirements for validity,...
To view the full article, register now.